Last reviewed · How we verify
NCT04114994: BoCA
Longitudinal Cognitive Assessment by BoCA
trial testing Boston Cognitive Assessment (BoCA) in Alzheimer Disease in 10,000 participants. Currently enrolling.
1 October 2029
Quick facts
| Lead sponsor | Alzheimer's Light LLC |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 October 2019 |
| Primary completion | 1 October 2029 |
| Estimated completion | 1 October 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Boston Cognitive Assessment (BoCA)
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Vascular Dementia — all drugs for Vascular Dementia →
- Frontotemporal Dementia — all drugs for Frontotemporal Dementia →
Sponsor
Alzheimer's Light LLC
Who can join
50 and older, any sex, with Alzheimer Disease or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04114994
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Alzheimer's Light LLC trials
Trials by the same sponsor.
- NCT03657745 — Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04114994 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alzheimer's Light LLC
- Last refreshed: 1 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04114994.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing